Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
23,038
Total Claims
$8.1M
Drug Cost
598
Beneficiaries
$14K
Cost/Patient
Risk Score Breakdown 18/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+858%
Cost per patient vs peers
$14K vs $1,411 avg
+161%
Brand preference vs peers
27.7% vs 10.6% avg
🔎 Data Overview
Cost per patient is 858% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Brand vs Generic
Brand: 6,249 claims · $7.3M
Generic: 16,272 claims · $777K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Icosapent Ethyl | 1,327 | $1.3M |
| Dapagliflozin Propanediol | 373 | $608K |
| Tenofovir Alafenamide | 245 | $491K |
| Lipase/Protease/Amylase | 129 | $445K |
| Semaglutide | 195 | $418K |
| Mirabegron | 410 | $397K |
| Linaclotide | 208 | $272K |
| Denosumab | 146 | $251K |
| Diclofenac Epolamine | 196 | $245K |
| Empagliflozin | 148 | $223K |
| Sitagliptin Phosphate | 117 | $185K |
| Apixaban | 111 | $183K |
| Vibegron | 142 | $180K |
| Azilsartan Medoxomil | 255 | $167K |
| Alirocumab | 110 | $148K |
Prescribing Profile
Patient Profile
75
Avg Age
46%
Female
1.21
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data